ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Walmrath, D
Right arrow Articles by Seeger, W
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Walmrath, D
Right arrow Articles by Seeger, W
Eur Respir J 1997; 10: 1084-1092
Copyright © ERS Journals Ltd 1997

Original Articles

Effects of inhaled versus intravenous vasodilators in experimental pulmonary hypertension

D Walmrath, R Schermuly, J Pilch, F Grimminger, and W Seeger

Inhaled nitric oxide (NO) causes selective pulmonary vasodilation and improves gas exchange in acute lung failure. In experimental pulmonary hypertension, we compared the influence of the aerosolized vasodilatory prostaglandins (PG) PGI2 and PGE1 on vascular tone and gas exchange to that of infused prostanoids (PGI2, PGE1) and inhaled NO. An increase of pulmonary artery pressure (Ppa) from 8 to approximately 34 mmHg was provoked by continuous infusion of U-46619 (thromboxane A2 (TxA2) analogue) in blood-free perfused rabbit lungs. This was accompanied by formation of moderate lung oedema and severe ventilation-perfusion (V'/Q') mismatch, with predominance of shunt flow (>50%, assessed by the multiple inert gas elimination technique). When standardized to reduce the Pps by approximately 10 mmHg, inhaled NO (200 ppm), aerosolized PGI2 (4 ng x kg(-1) x min(-1)) and nebulized PGE1 (8 ng x kg(-1) x min(-1)) all reduced both pre- and postcapillary vascular resistance, but did not affect formation of lung oedema. All inhalative agents improved the V'/Q' mismatch and reduced shunt flow, the rank order of this capacity being NO > PGI2 > PGE1. In contrast, lowering of Ppa by intravascular administration of PGI2 and PGE1 did not improve gas exchange. "Supratherapeutic" doses of inhaled vasodilators in control lungs (400 ppm NO, 30 ng x kg(-1) x min(-1) of PGI2 or PGE1) did not provoke vascular leakage or affect the physiological V'/Q' matching. We conclude that aerosolization of prostaglandins I2 and E1 is as effective as inhalation of nitric oxide in relieving pulmonary hypertension. When administered via this route instead of being infused intravascularly, the prostanoids are capable of improving ventilation-perfusion matching, suggesting selective vasodilation in well-ventilated lung areas.


This article has been cited by other articles:


Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
H. H. Leuchte, T. Meis, M. El-Nounou, J. Michalek, and J. Behr
Inhalation of endothelin receptor blockers in pulmonary hypertension
Am J Physiol Lung Cell Mol Physiol, April 1, 2008; 294(4): L772 - L777.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
P. Goyal, U. Kiran, S. Chauhan, R. Juneja, and M. Choudhary
Efficacy of nitroglycerin inhalation in reducing pulmonary arterial hypertension in children with congenital heart disease
Br. J. Anaesth., August 1, 2006; 97(2): 208 - 214.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
R.T. Schermuly, H. Leuchte, H.A. Ghofrani, N. Weissmann, F. Rose, M. Kohstall, H. Olschewski, C. Schudt, F. Grimminger, W. Seeger, et al.
Zardaverine and aerosolised iloprost in a model of acute respiratoryfailure
Eur. Respir. J., August 1, 2003; 22(2): 342 - 347.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
R. T. Schermuly, A. Roehl, N. Weissmann, H. A. Ghofrani, H. Leuchte, F. Grimminger, W. Seeger, and D. Walmrath
Combination of nonspecific PDE inhibitors with inhaled prostacyclin in experimental pulmonary hypertension
Am J Physiol Lung Cell Mol Physiol, December 1, 2001; 281(6): L1361 - L1368.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
D. C. Stuesse, G. D. Giraud, A. A. Vlessis, A. Starr, and D. D. Trunkey
Hemodynamic effects of S-nitrosocysteine, an intravenous regional vasodilator
J. Thorac. Cardiovasc. Surg., August 1, 2001; 122(2): 371 - 377.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
R. T. Schermuly, N. Weissmann, B. Enke, H. A. Ghofrani, W. G. Forssmann, F. Grimminger, W. Seeger, and D. Walmrath
Urodilatin, a Natriuretic Peptide Stimulating Particulate Guanylate Cyclase, and the Phosphodiesterase 5 Inhibitor Dipyridamole Attenuate Experimental Pulmonary Hypertension . Synergism upon Coapplication
Am. J. Respir. Cell Mol. Biol., August 1, 2001; 25(2): 219 - 225.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
H. Maurenbrecher, M. Lamy, G. Deby-Dupont, P. Frascarolo, and G. Hedenstierna
An Animal Model of Response and Nonresponse to Inhaled Nitric Oxide in Endotoxin-Induced Lung Injury
Chest, August 1, 2001; 120(2): 573 - 581.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
H. Schutte, A. Lockinger, W. Seeger, and F. Grimminger
Aerosolized PGE1, PGI2 and nitroprusside protect against vascular leakage in lung ischaemia-reperfusion
Eur. Respir. J., July 1, 2001; 18(1): 15 - 22.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
P. Schenk, V. Petkov, C. Madl, L. Kramer, M. Kneussl, R. Ziesche, and I. Lang
Aerosolized Iloprost Therapy Could Not Replace Long-term IV Epoprostenol (Prostacyclin) Administration in Severe Pulmonary Hypertension
Chest, January 1, 2001; 119(1): 296 - 300.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
R. A. Schroeder, G. L. Wood, J. S. Plotkin, and P. C. Kuo
Intraoperative Use of Inhaled PGI2 for Acute Pulmonary Hypertension and Right Ventricular Failure
Anesth. Analg., August 1, 2000; 91(2): 291 - 295.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. T. Schermuly, A. Roehl, N. Weissmann, H. A. Ghofrani, C. Schudt, H. Tenor, F. Grimminger, W. Seeger, and D. Walmrath
Subthreshold Doses of Specific Phosphodiesterase Type 3 and 4 Inhibitors Enhance the Pulmonary Vasodilatory Response to Nebulized Prostacyclin with Improvement in Gas Exchange
J. Pharmacol. Exp. Ther., February 1, 2000; 292(2): 512 - 520.
[Abstract] [Full Text]

Home page
 ThoraxHome page
A J Peacock
Rare diseases bullet 5: Primary pulmonary hypertension
Thorax, December 1, 1999; 54(12): 1107 - 1118.
[Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. T. SCHERMULY, H. A. GHOFRANI, B. ENKE, N. WEISSMANN, F. GRIMMINGER, W. SEEGER, C. SCHUDT, and D. WALMRATH
Low-dose Systemic Phosphodiesterase Inhibitors Amplify the Pulmonary Vasodilatory Response to Inhaled Prostacyclin in Experimental Pulmonary Hypertension
Am. J. Respir. Crit. Care Med., November 1, 1999; 160(5): 1500 - 1506.
[Abstract] [Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
G. HERMLE, H. SCHÜTTE, D. WALMRATH, K. GEIGER, W. SEEGER, and F. GRIMMINGER
Ventilation-Perfusion Mismatch after Lung Ischemia-Reperfusion . Protective Effect of Nitric Oxide
Am. J. Respir. Crit. Care Med., October 1, 1999; 160(4): 1179 - 1187.
[Abstract] [Full Text]

Home page
 Anesth. Analg.Home page
M. Aranda, K. K. Bradford, and R. G. Pearl
Combined Therapy with Inhaled Nitric Oxide and Intravenous Vasodilators During Acute and Chronic Experimental Pulmonary Hypertension
Anesth. Analg., July 1, 1999; 89(1): 152 - 152.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the European Respiratory Society.